Relationship Between Cd74 Levels, Macrophage  Migration Inhibitory Factor Gene Polymorphism,  and Clinical Features in Patients with Ankylosing  Spondylitis

Mazlum Serdar Akaltun; Sacide Pehlivan; Tekin Karslıgil; Özlem Altındağ; Ali Aydeniz; Ali Gür; Savaş Gürsoy

doi:10.5152/eurjther.2019.19048

Authors

Mazlum Serdar Akaltun Department of Physical Medicine and Rehabilitaton, Gaziantep University School of Medicine, Gaziantep https://orcid.org/0000-0002-9666-9483
Sacide Pehlivan Department of Medical Biology, İstanbul University School of Medicine, İstanbul https://orcid.org/0000-0003-1272-5845
Tekin Karslıgil Department of Medical Microbiology, Gaziantep University School of Medicine, Gaziantep https://orcid.org/0000-0001-7672-3625
Özlem Altındağ Department of Physical Medicine and Rehabilitaton, Gaziantep University School of Medicine, Gaziantep https://orcid.org/0000-0003-1119-2987
Ali Aydeniz Department of Physical Medicine and Rehabilitaton, Gaziantep University School of Medicine, Gaziantep https://orcid.org/0000-0001-5701-3951
Ali Gür Department of Physical Medicine and Rehabilitaton, Gaziantep University School of Medicine, Gaziantep https://orcid.org/0000-0001-9680-6268
Savaş Gürsoy Department of Physical Medicine and Rehabilitaton, Gaziantep University School of Medicine, Gaziantep https://orcid.org/0000-0002-1673-9905

DOI:

https://doi.org/10.5152/eurjther.2019.19048

Keywords:

Ankylosing spondylitis, CD74, MIF gene, polymorphism

Abstract

Objective: Firstly, in this study, we aimed to compare CD74 antigen levels between patients with ankylosing spondylitis (AS) and healthy controls. Secondly, we investigated the distribution of macrophage migration inhibitory factor (MIF) 173 G/C polymorphisms in patients with AS and the control group. Finally, we determined the relationship between CD74 antigen levels and MIF 173 G/C polymorphism.
Methods: We enrolled 82 healthy blood donors and 79 patients with AS. MIF 173 G/C polymorphism and CD74 levels in the patient and control groups were investigated using enzyme-linked immunosorbent assay. Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Metrology Index (BASMI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Radiology Index (BASRI), Visual Analogue Scale (VAS), and Ankylosing Spondylitis Quality of Life (AS-QoL) scores were calculated and recorded.
Results: No significant difference was observed between the patient and control groups in terms of age, gender, and body mass index. The median CD74 level in the patient group was 1.17 (0.93-2.1), which was significantly lower than that in the control group [2.16 (1.6-4.41)]. CD74 antigen levels were not correlated with BASDAI, BASMI, BASFI, BASRI, VAS, and AS-QoL scores. The number of patients with the C allele was higher in the patient group than in the control group; however, the difference was not statistically significant (p>0.05). Moreover, no correlation was observed between the genotypes and BASDAI, BASMI, BASFI, BASRI, VAS, and AS-QoL scores (p>0.05). The comparison of median CD74 levels among individuals in the patient group according to their HLA-B27 status and genotypes did not reveal any statistically significant difference.
Conclusion: As a result, we think that CD 74 antigen levels can be used in the diagnosis of AS. More studies are needed for the role of MIF gene polymorphism in etiology.

Metrics

Metrics Loading ...

References

Dougados M, Baeten D. Spondyloarthritis. Lancet 2011; 377: 2127-37.

Daikh DI, Chen PP. Advances in managing ankylosing spondylitis. F1000Prime Reports 2014; 6: 78.

Bandinelli F, Salvadorini G, Delle Sedie A, Riente L, Bombardieri S, Matucci-Cerinic M. Impact of gender, work, and clinical resentation on diagnostic delay in Italian patients with primary ankylosing spondylitis. Clin Rheumatol 2016; 35: 473-8.

Mercieca C, Landewe R, Borg AA. Spondylarthropathies Pathogenesis and Clinical Features. In: Bijlsma JWJ, Silva JAP, Hachulla E, Doherty M, Cope E, Liote F. Eular Textbook on Rheumatic Diseases. 1st ed. London: BMJ Group; 2012.p.255-75.

Chen B, Li J, He C, Li D, Tong W, Zou Y, et al. Role of HLA-B27 in the pathogenesis of ankylosing spondylitis. Mol Med Rep 2017; 15: 1943-51.

Davidson SI, Wu X, Liu Y, Wei M, Danoy PA, Thomas G, et al. Association of ERAP1, but not IL23R, with ankylosing spondylitis in a an Chinese population. Arthritis Rheum 2009; 60; 3263-8.

Brown MA. Genetics of ankylosing spondylitis. Curr Opin Rheumatol 2010; 22: 126-32.

Baerlecken NT, Nothdorft S, Stummvoll GH, Sieper J, Rudwaleit M, Reuter S, et al. Autoantibodies against CD74 in spondyloarthritis. Ann Rheum Dis 2014; 73: 1211-4.

Schneppenheim J, Loock AC, Hüttl S, Schweizer M, Lüllmann-Rauch R, Oberg HH, et al. The ınfluence of MHC Class II on B cell defects ınduced by ınvariant Chain/CD74 N-Terminal fragments. J Immunol 2017; 199: 172-85.

Kim KW, Kim HR. Macrophage migration inhibitory factor: a potential therapeutic target for rheumatoid arthritis. Korean J Intern Med 2016; 31: 634-42.

Kasama T, Ohtsuka K, Sato M, Takahashi R, Wakabayashi K, Kobayashi K. Macrophage migration inhibitory factor: a multifunctional cytokine in rheumatic diseases. Arthritis 2010; 2010: 106202.

Santos L, Hall P, Metz C, Bucala R, Morand EF. Role of macrophage migration inhibitory factor (MIF) in murine antigen‐induced arthritis: interaction with glucocorticoids. Clin Exp Immunol 2001: 123: 309-14.

Yang J, Li Y, Zhang X. Meta-analysis of macrophage migration inhibitory factor (MIF) gene-173G/C polymorphism and inflammatory bowel disease (IBD) risk. Int J Clin Exp Med 2015; 8: 9570-4.

Nishihira J. Molecular fuction of macrophace migration factor and a novel therapy for inflammotory bowel disease. Ann NY Acad Sci 2012; 1271: 53-7.

Bucala R, Shachar I. The integral role of CD74 in antigen presentation, MIF signal transduction, and B cell survival and homeostasis. Mini Rev Med Chem 2014; 14: 1132-8.

Brown MA, Kenna T, Wordsworth BP. Genetics of ankylosing spondylitis-insights into pathogenesis. Nat Rev Rheumatol 2016; 12: 81-91.

Bucala R. MIF, MIF alleles, and prospects for therapeutic intervention in autoimmunity. J Clin Immunol 2013; 33: 72-8.

Calandra T, Bucala R. Macrophage migration inhibitory factor (MIF): a glucocorticoid counter-regulator within the immune system. Crit Rev Immunol 2017; 37: 2-6.

Ohkawara T, Nishihira J, Takeda H, Hige S, Kato M, Sugiyama T, et al. Amelioration of dextran sulfate sodium–induced colitis by anti-macrophage migration inhibitory factor antibody in mice. Gastroenterology 2002; 123: 256-70.

Martínez A, Orozco G, Varadé J, Sánchez López M, Pascual D, Balsa A, et al. Macrophage migration inhibitory factor gene: influence on rheumatoid arthritis susceptibility. Hum Immunol 2007; 68: 744-7.

Radstake TR, Sweep FC, Welsing P, Franke B, Vermeulen SH, GeurtsMoespot A, et al. Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis Rheum 2005; 52: 3020-9.

Zheng X, Wang D, Hou S, Zhang C, Lei B, Xiao X, et al. Association of macrophage migration inhibitory factor gene polymorphisms with Behcet’s disease in a Han Chinese population. Ophthalmology 2012; 119: 2514-8.

Przybyłowska K, Mrowicki J, Sygut A, Narbutt P, Dziki Ł, Dziki A, et al. Contribution of the-173 G/C polymorphism of macrophage migration inhibitory factor gene to the risk of inflammatory bowel diseases. Pol Przegl Chir 2011; 83: 76-80.

Gürel Ç, İnanır A, Nursal AF, Tekcan A, Rüstemoğlu A, Yigit S. Evaluation of MIF-173 G/C Polymorphism in Turkish Patients with Ankylosing Spondylitis. Balkan Med J 2016; 33: 614-9.

Borghese F, Clanchy FI. CD74: an emerging opportunity as therapeutic target in cancer and autoimmune disease. Expert Opin Ther Targets 2011; 15: 237-51.

Su H, Na N, Zhang X, Zhao Y. The biological function and significance of CD74 in immune diseases. J Inflamm Res 2017; 66: 209-16.

Baraliakos X, Baerlecken N, Witte T, Heldmann F, Braun J. High prevalence of anti-CD74 antibodies specific for the HLA class II-associated invariant chain peptide (CLIP) in patients with axial spondyloarthritis. Ann Rheum Dis 2014; 73: 1079-82.

Ranganathan V, Ciccia F, Zeng F, Sari I, Guggino G, Muralitharan J, et al. Macrophage Migration Inhibitory Factor induces inflammation and predicts spinal progression in Ankylosing Spondylitis. Arthritis Rheumatol 2017; 69: 1796-806.